This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The General Hospital Corporation. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: A John Iafrate: Innovator in Genetic Sequencing
Introduction
A John Iafrate is a prominent inventor based in Newton, MA (US). He has made significant contributions to the field of genetic sequencing, particularly in the development of ultra-sensitive assays for mutation detection. His work has implications for cancer diagnostics and personalized medicine.
Latest Patents
Iafrate holds a patent for "LNA-based mutant enrichment next-generation sequencing assays." This innovative assay is designed for the detection of mutations from blood-based sources of tumor genetic material, such as circulating tumor cells or plasma. It is particularly useful in scenarios where limited amounts of DNA are available, such as tumor DNA. The assay is exemplified in the estrogen receptor but is broadly customizable to target mutations in other genes. He has 1 patent to his name.
Career Highlights
Iafrate is associated with The General Hospital Corporation, where he continues to advance research in genetic sequencing. His work has been instrumental in enhancing the sensitivity and specificity of mutation detection assays, which are crucial for effective cancer treatment.
Collaborations
Iafrate has collaborated with notable colleagues, including Tilak K Sundaresan and Zongli Zheng. Their combined expertise has contributed to the development of innovative solutions in the field of genetic research.
Conclusion
A John Iafrate's contributions to genetic sequencing and mutation detection are paving the way for advancements in cancer diagnostics. His innovative approaches are essential for improving patient outcomes in the realm of personalized medicine.